![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.
Lead Product(s): Hyaluronic Acid Derived Therapy,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: ABV-1701
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.
Lead Product(s): Hyaluronic Acid Derived Therapy,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: ABV-1701
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
Vitargus (hyaluronic acid-derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Lead Product(s): Hyaluronic Acid-derived Therapy,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: Vitargus
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2022
Details:
ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.
Lead Product(s): Hyaluronic Acid,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: ABV-1701
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Vitargus (Hyaluronic Acid Derived Therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Lead Product(s): Hyaluronic Acid-derived Therapy,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: Vitargus
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Vitargus/ABV-1701 (hyaluronic acid derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Lead Product(s): Hyaluronic Acid Derived Therapy,Adipic Dihydrazide
Therapeutic Area: Ophthalmology Product Name: ABV-1701
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022